BMEA vs. HRTX, BNTC, TECX, RGNX, PHAT, ATYR, AMLX, CMPX, CYRX, and CMPS
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Heron Therapeutics (HRTX), Benitec Biopharma (BNTC), Tectonic Therapeutic (TECX), REGENXBIO (RGNX), Phathom Pharmaceuticals (PHAT), Atyr PHARMA (ATYR), Amylyx Pharmaceuticals (AMLX), Compass Therapeutics (CMPX), Cryoport (CYRX), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry.
Biomea Fusion vs.
Biomea Fusion (NASDAQ:BMEA) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.
96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by insiders. Comparatively, 5.8% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Biomea Fusion presently has a consensus target price of $24.64, suggesting a potential upside of 971.15%. Heron Therapeutics has a consensus target price of $5.67, suggesting a potential upside of 150.74%. Given Biomea Fusion's higher possible upside, equities research analysts plainly believe Biomea Fusion is more favorable than Heron Therapeutics.
Heron Therapeutics received 607 more outperform votes than Biomea Fusion when rated by MarketBeat users. However, 68.97% of users gave Biomea Fusion an outperform vote while only 68.83% of users gave Heron Therapeutics an outperform vote.
Heron Therapeutics has higher revenue and earnings than Biomea Fusion. Heron Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biomea Fusion had 14 more articles in the media than Heron Therapeutics. MarketBeat recorded 16 mentions for Biomea Fusion and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.72 beat Biomea Fusion's score of 0.36 indicating that Heron Therapeutics is being referred to more favorably in the news media.
Biomea Fusion has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.31%. Heron Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.
Biomea Fusion has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.
Summary
Biomea Fusion beats Heron Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Biomea Fusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
This page (NASDAQ:BMEA) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy BMEA Stock Free BMEA Stock Alerts